FARMINGDALE, N.Y., Feb. 3, 2015 /PRNewswire/ — Misonix, Inc. (Nasdaq: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced that it has entered into an agreement with Aesculap, Inc. to acquire back the rights to the remaining accounts, as of March 1, 2015, exclusively being managed by Aesculap for the Misonix BoneScalpel Ultrasonic Bone Cutting System.
Since December 2012, under a non-exclusive distribution agreement, Aesculap retained the right to sell BoneScalpel disposables in the United States to certain, limited hospital accounts which are covered by binding supply agreements for varying periods of time, but not to exceed 3 years. The BoneScalpel is a novel ultrasonic surgical system used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
“We are thankful to Aesculap and their professional management of, and efforts in, servicing these strategically important accounts,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. Mr. McManus goes on to say, “This new agreement moves Misonix an important additional step further along the path of complete control of BoneScalpel distribution in the United Statesthrough the company’s own growing network of sales representatives.”
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billionannually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site atwww.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.